patents.google.com

DOP2002000482A - PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS - Google Patents

️Sat May 31 2003

DOP2002000482A - PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS - Google Patents

PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS

Info

Publication number

DOP2002000482A

DOP2002000482A DO2002000482A DO2002000482A DOP2002000482A DO P2002000482 A DOP2002000482 A DO P2002000482A DO 2002000482 A DO2002000482 A DO 2002000482A DO 2002000482 A DO2002000482 A DO 2002000482A DO P2002000482 A DOP2002000482 A DO P2002000482A Authority

Dominican Republic

Prior art keywords

alkyl

optionally substituted

treatment

pde9 inhibitors

cardiovascular disorders

Prior art date

2001-11-02

Application number

DO2002000482A

Other languages

Spanish (es)

Inventor

Mark Ian Kemp

Anthony Wood

Michael Paul Deninno

Bernadette Hughes

Michael John Palmer

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-02

Filing date

2002-10-09

Publication date

2003-05-31

2001-11-02 Priority claimed from GB0126395A external-priority patent/GB0126395D0/en

2001-12-21 Priority claimed from GB0130695A external-priority patent/GB0130695D0/en

2002-07-18 Priority claimed from GB0216761A external-priority patent/GB0216761D0/en

2002-10-09 Application filed by Pfizer filed Critical Pfizer

2003-05-31 Publication of DOP2002000482A publication Critical patent/DOP2002000482A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Gynecology & Obstetrics (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pregnancy & Childbirth (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Obesity (AREA)
Toxicology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a los inhibidores PDE9 para el tratamiento de trastornos cardiovasculares. Los inhibidores PDE9 preferidos son compuestos de la fórmula I en los que R1 es H o alquilo C1-6, en el que R1 está unido bien a N1 o N2; R2 es alquilo C16 opcionalmente sustituido con hidroxi o alcoxi; cicloalquilo C3-7, opcionalmente sustituido con alquilo, hidroxi, o alcoxi; un heterociclo saturado de 5-6 miembros opcionalmente sustituido con alquilo, ,hidroxi o alcoxi; het o Ar1 R3 es alquilo c-6 opcionalmente sustituido con 1 ó 2 grupos independientemente seleccionados entre: Ar2 cicloalquilo C3-7, opcionalmente sustituido con alquilo C,6 OAr2 SAr2 NHCO alquilo C,.6 het2 xanteno; y naft1eno.The invention relates to PDE9 inhibitors for the treatment of cardiovascular disorders. Preferred PDE9 inhibitors are compounds of the formula I in which R1 is H or C1-6 alkyl, wherein R1 is well linked to N1 or N2; R2 is C16 alkyl optionally substituted with hydroxy or alkoxy; C3-7 cycloalkyl, optionally substituted with alkyl, hydroxy, or alkoxy; a saturated 5-6 membered heterocycle optionally substituted with alkyl, hydroxy or alkoxy; het or Ar1 R3 is C-6 alkyl optionally substituted with 1 or 2 groups independently selected from: Ar2 C3-7 cycloalkyl, optionally substituted with C alkyl, 6 OAr2 SAr2 NHCO C alkyl, .6 het2 xanthene; and naphthine.

DO2002000482A 2001-11-02 2002-10-09 PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS DOP2002000482A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0126395A GB0126395D0 (en)	2001-11-02	2001-11-02	Pyrazolo[4,3]pyrimidine derivatives and their use in treating disease
GB0130695A GB0130695D0 (en)	2001-12-21	2001-12-21	Pyrazola[4,3]pyrimidine
GB0216761A GB0216761D0 (en)	2002-07-18	2002-07-18	PDE9 Inhibitors for treating cardiovascular disorders

Publications (1)

Publication Number	Publication Date
DOP2002000482A true DOP2002000482A (en)	2003-05-31

Family

ID=27256310

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DO2002000482A DOP2002000482A (en)	2001-11-02	2002-10-09	PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS

Country Status (14)

Country	Link
EP (1)	EP1440073A1 (en)
JP (1)	JP2005511575A (en)
AR (1)	AR037329A1 (en)
BR (1)	BR0214096A (en)
CA (1)	CA2466824A1 (en)
DO (1)	DOP2002000482A (en)
HN (1)	HN2002000317A (en)
MX (1)	MXPA04004171A (en)
PA (1)	PA8557401A1 (en)
PE (1)	PE20030702A1 (en)
SV (1)	SV2004001373A (en)
TW (1)	TW200300081A (en)
UY (1)	UY27522A1 (en)
WO (1)	WO2003037899A1 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
EP1575916B1 (en)	2001-08-31	2013-05-22	The Rockefeller University	Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CA2468156A1 (en)	2001-12-06	2003-06-19	Merck & Co., Inc.	Azolopyrimidinone compounds and their use
DE10238723A1 (en)	2002-08-23	2004-03-11	Bayer Ag	Phenyl substituted pyrazolyprimidines
DE10238722A1 (en)	2002-08-23	2004-03-11	Bayer Ag	Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
DE10238724A1 (en)	2002-08-23	2004-03-04	Bayer Ag	New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
US7141669B2 (en)	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US8044060B2 (en)	2003-05-09	2011-10-25	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
WO2004099211A1 (en) *	2003-05-09	2004-11-18	Bayer Healthcare Ag	6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
DE102004004142A1 (en) *	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
DE10320785A1 (en)	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-arylmethyl substituted pyrazolopyrimidines
DE10328479A1 (en)	2003-06-25	2005-01-13	Bayer Ag	6-arylamino-5-cyano-4-pyrimidinones
MXPA06000794A (en)	2003-07-22	2006-08-23	Astex Therapeutics Ltd	3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators.
DE102004001873A1 (en)	2004-01-14	2005-09-29	Bayer Healthcare Ag	Cyanopyrimidinone
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
US7067659B2 (en) *	2004-04-23	2006-06-27	Duke University	Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (en)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
DE102005024494A1 (en) *	2005-05-27	2006-11-30	Bayer Healthcare Ag	Use of cyanopyrimidines
EP1908765B1 (en)	2005-06-14	2014-10-22	ASKA Pharmaceutical Co., Ltd.	Thienopyrimidine derivative
US20080194592A1 (en) *	2005-08-23	2008-08-14	Intra-Cellular Therapies, Inc.	Organic Compounds
MX2008015489A (en)	2006-06-06	2009-01-13	Intra Cellular Therapies Inc	Organic compounds.
CA2659967C (en)	2006-08-08	2014-05-13	Aska Pharmaceutical Co., Ltd.	Quinazoline derivatives
US8299080B2 (en) *	2006-12-13	2012-10-30	Aska Pharmaceutical Co., Ltd.	Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
CN101557826A (en) *	2006-12-13	2009-10-14	Aska制药株式会社	Therapeutic agent for urinary tract disease
EP2129218B1 (en) *	2007-02-16	2016-10-19	Emisphere Technologies, Inc.	Compounds having a cyclic moiety and compositions for delivering active agents
SI2152712T1 (en) *	2007-05-11	2012-03-30	Pfizer	Amino-heterocyclic compounds
EP2217602B1 (en) *	2007-11-30	2018-08-29	Boehringer Ingelheim International GmbH	1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
MX2010006208A (en)	2007-12-06	2010-12-21	Intra Cellular Therapies Inc	Organic compounds.
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2334684B1 (en)	2008-09-08	2017-08-02	Boehringer Ingelheim International GmbH	Pyrazolopyrimidines and their use for the treatment of cns disorders
MX2011004258A (en)	2008-10-22	2011-06-01	Merck Sharp & Dohme	Novel cyclic benzimidazole derivatives useful anti-diabetic agents.
US8329914B2 (en)	2008-10-31	2012-12-11	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8697710B2 (en)	2008-12-06	2014-04-15	Intra-Cellular Therapies, Inc.	Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones
MA32941B1 (en)	2008-12-06	2012-01-02	Intra Cellular Therapies Inc	Organic compounds
EP2367428B1 (en)	2008-12-06	2016-04-06	Intra-Cellular Therapies, Inc.	Organic compounds
TWI404721B (en)	2009-01-26	2013-08-11	Pfizer	Amino-heterocyclic compounds
ES2612954T3 (en)	2009-03-05	2017-05-19	Astellas Pharma Inc.	Quinoxaline Compounds
EP2414363B1 (en)	2009-03-31	2014-01-08	Boehringer Ingelheim International GmbH	1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
WO2011016861A2 (en)	2009-08-05	2011-02-10	Intra-Cellular Therapies, Inc.	Novel regulatory proteins and inhibitors
EP2538784B1 (en)	2010-02-25	2015-09-09	Merck Sharp & Dohme Corp.	Benzimidazole derivatives useful anti-diabetic agents
EP2590657A4 (en)	2010-05-31	2014-02-12	Intra Cellular Therapies Inc	Organic compounds
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
WO2012004900A1 (en) *	2010-07-09	2012-01-12	Aska Pharmaceutical Co., Ltd.	Thienopyrimidine compounds
KR101918909B1 (en)	2010-08-12	2018-11-15	베링거 인겔하임 인터내셔날 게엠베하	6-cycloalkyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
BR112013005439A2 (en)	2010-09-07	2017-09-19	Astellas Pharma Inc	quinoxaline compounds
JP5888237B2 (en)	2010-09-07	2016-03-16	アステラス製薬株式会社	Pyrazoloquinoline compounds
WO2012076435A1 (en) *	2010-12-06	2012-06-14	Glaxo Group Limited	Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
PE20140859A1 (en)	2011-02-25	2014-07-25	Merck Sharp & Dohme	NOVELTY DERIVATIVES OF CYCLIC AZABENZIMIDAZOLE USEFUL AS ANTIDIABETIC AGENTS
EP2906562B1 (en) *	2011-10-10	2016-10-05	H. Lundbeck A/S	Pde9i with imidazo pyrazinone backbone
AU2013213603B2 (en)	2012-01-26	2017-02-02	H. Lundbeck A/S	PDE9 inhibitors with imidazo triazinone backbone
RU2015106909A (en)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	ANTI-DIABETIC TRICYCLIC COMPOUNDS
CN102786525B (en)	2012-08-08	2014-12-17	中山大学	N-substituted pyrazolo [3, 4-d] pyrimidine ketone compound and preparation method and application thereof
US9840512B2 (en)	2013-02-22	2017-12-12	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
EP3303339B1 (en)	2015-07-07	2021-01-13	H. Lundbeck A/S	Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298A4 (en)	2016-12-20	2020-08-05	Merck Sharp & Dohme Corp.	ANTIDIABETIC SPIROCHROMAN COMPOUNDS
EP3630113A4 (en)	2017-06-01	2021-02-24	Eisai R&D Management Co., Ltd.	PHARMACEUTICAL COMPOSITION, INCLUDING PDE9 INHIBITOR
ES2980131T3 (en)	2017-06-01	2024-09-30	Eisai R&D Man Co Ltd	Therapeutic agent for dementia that combines pyrazoloquinoline derivative and donepezil
SG11201909590XA (en)	2017-06-01	2019-11-28	Eisai R&D Man Co Ltd	Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
JP7269875B2 (en)	2017-06-01	2023-05-09	エーザイ・アール・アンド・ディー・マネジメント株式会社	Lewy Body Disease Treatment Agent Containing Pyrazoloquinoline Derivative
KR20210014662A (en)	2018-05-25	2021-02-09	이마라 인크.	6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1, 5-a]Pyrazin-8-one monohydrate and crystalline form
EP3843737A4 (en)	2018-08-31	2022-06-01	Imara Inc.	PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
CN111658653B (en) *	2019-03-08	2022-09-09	药捷安康(南京)科技股份有限公司	Use of phosphodiesterase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
US3939161A (en) *	1973-10-29	1976-02-17	Abbott Laboratories	1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones
US4666908A (en) *	1985-04-05	1987-05-19	Warner-Lambert Company	5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
GB9722520D0 (en) *	1997-10-24	1997-12-24	Pfizer Ltd	Compounds
DE19838705A1 (en) *	1998-08-26	2000-03-02	Bayer Ag	New dihydro- (1,2,3) -triazolo- [4,5-d] pyrimidin-7-ones
IL139457A0 (en) *	1999-11-08	2001-11-25	Pfizer	Compounds for the treatment of female sexual dysfunction
WO2002062799A1 (en) *	2001-02-05	2002-08-15	Dr. Reddy's Laboratories Ltd.	Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents

2002
- 2002-10-01 HN HN2002000317A patent/HN2002000317A/en unknown
- 2002-10-09 DO DO2002000482A patent/DOP2002000482A/en unknown
- 2002-10-22 BR BR0214096-9A patent/BR0214096A/en not_active IP Right Cessation
- 2002-10-22 CA CA002466824A patent/CA2466824A1/en not_active Abandoned
- 2002-10-22 EP EP02777623A patent/EP1440073A1/en not_active Withdrawn
- 2002-10-22 WO PCT/IB2002/004385 patent/WO2003037899A1/en not_active Application Discontinuation
- 2002-10-22 JP JP2003540180A patent/JP2005511575A/en active Pending
- 2002-10-22 MX MXPA04004171A patent/MXPA04004171A/en unknown
- 2002-10-29 PA PA20028557401A patent/PA8557401A1/en unknown
- 2002-10-30 UY UY27522A patent/UY27522A1/en not_active Application Discontinuation
- 2002-10-30 PE PE2002001070A patent/PE20030702A1/en not_active Application Discontinuation
- 2002-10-31 AR ARP020104152A patent/AR037329A1/en unknown
- 2002-11-01 TW TW091132424A patent/TW200300081A/en unknown
- 2002-11-01 SV SV2002001373A patent/SV2004001373A/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2466824A1 (en)	2003-05-08
EP1440073A1 (en)	2004-07-28
PA8557401A1 (en)	2003-11-12
PE20030702A1 (en)	2003-08-21
WO2003037899A1 (en)	2003-05-08
SV2004001373A (en)	2004-01-07
JP2005511575A (en)	2005-04-28
AR037329A1 (en)	2004-11-03
BR0214096A (en)	2004-09-28
MXPA04004171A (en)	2004-09-06
HN2002000317A (en)	2003-05-21
TW200300081A (en)	2003-05-16
UY27522A1 (en)	2003-06-30

Publication	Publication Date	Title
DOP2002000482A (en)	2003-05-31	PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
ECSP055640A (en)	2005-07-06	PIRAZOL COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3
UY27234A1 (en)	2002-10-31	NOVELTY INHIBITORS OF TYROSINE KINASE
ECSP088858A (en)	2008-12-30	USE OF ARILCARBOXYL ACID BIFENYLAMIDES FOR SEED TREATMENT
AR063015A1 (en)	2008-12-23	DERIVATIVES OF QUINAZOLINONA 5-SUBSTITUTE AND COMPOSITIONS THAT INCLUDE THEM AND METHODS TO USE THEM IN THE TREATMENT OF CANCER
NO20054970L (en)	2006-01-11	Aryl-substituted byrazole compounds useful as kinase inhibitors
CY1105386T1 (en)	2010-04-28	BENZYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTI-BULK AGENTS
AR045595A1 (en)	2005-11-02	USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS
AR054475A1 (en)	2007-06-27	PHENYLPHOSPHATES SUBSTITUTED AS MUTUAL PROPHARMACES OF STEROIDS AND (BETA) -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCOCONSTRICTION
AR036365A1 (en)	2004-09-01	1,8-NAFTIRIDIN-4 (1H) -THE ALQUIN-ARIL SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ECSP024382A (en)	2003-02-06	SERINA PROTEASE INHIBITORS
ECSP056097A (en)	2006-03-01	CGRP RECEIVER ANTAGONISTS
NO20031001L (en)	2003-03-04	Polyarylcarboxamides useful as lipid-lowering agents
SE0302232D0 (en)	2003-08-18	Novel Compounds
UY29061A1 (en)	2006-03-31	PROCEDURE FOR THE PREPARATION OF DIHYDROPTERIDINONES
EA200501928A1 (en)	2006-12-29	Pyrrolodihydroisoquinols as inhibitors of PDE10
ECSP10010473A (en)	2010-10-30	NEW DERIVATIVES OF CARBAZOL, INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE
NO20062417L (en)	2006-05-26	N-thiazol-2-yl-benzamide
DK1761520T3 (en)	2008-10-27	kinase inhibitors
NO20052884L (en)	2005-08-15	Substituted indolpyridine compounds as anti-infective agents.
DOP2001000205A (en)	2002-12-15	DERIVATIVES OF CYCLOPENTIL-GLUTARAMIDE AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE
DE60214990D1 (en)	2006-11-09	BENZOLSULFONIC ACID ESTERS INDOL-5-YL AS 5-HT6 RECEPTOR ANTAGONISTS
EA200801366A1 (en)	2008-10-30	DERIVATIVES 3,6-DIGIDRO-2-OXO-6N-1,3,4-TIADIAZINA
NO20033959D0 (en)	2003-09-08	Benzimidazoles useful in the treatment of sexual dysfunction
CO5590858A2 (en)	2005-12-30	FUNGICIDE COMPOSITION BASED ON A PYRIDILMETILBENZAMIDA AND IPROVALICARB DERIVATIVE

DOP2002000482A - PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS - Google Patents